semaglutide mash targets molecular pathways beyond weight loss Wegovy® (semaglutide injection) Receives Conditional

Metabolite pathway sets were downloaded from the Small Molecule Pathway Database (SMPDB) (71), and metabolite set enrichment was tested using the limma ROAST method (72)

Using a library of immunoassays and a sensitive MS-based platform [20], we have identified fragment(s) identical to the anticipated sequences that would be produced by endoproteolytic cleavage of GLP-1(936)NH 2 by the NEP 24.11 enzyme [11], including DVSSYLEGQAAKE [GLP-1(1527)NH 2 ] and FIAWLVKGR-NH 2 [GLP-1(2836)NH 2 ], consistent with cleavage of GLP-1 in the mid region of the peptide (EGTFTSDVSSYLEGQAAKE-FIAWLVKGR)

5,7,8 The magnitude of weight loss is a significant factor in the potential benefit of GLP-1RAs in HFpEF patients with obesity

However, because it can promote the growth of new blood vessels, most researchers advise against using it if you have active or suspected cancer